XM does not provide services to residents of the United States of America.

Bayer's first-quarter adjusted profit falls less than expected

<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 2-Bayer's first-quarter adjusted profit falls less than expected</title></head><body>

Recasts, adds details, background on job cuts from paragraph 11

By Ludwig Burger

FRANKFURT, May 14 (Reuters) -Bayer BAYGn.DE beat first-quarter analyst forecasts as it reported a slight drop in adjusted earnings on Tuesday, providing a respite for the CEO's turnaround efforts.

The group also lowered its full-year earnings outlook, citing negative currency effects, but retained its operating forecast.

The company's quarterly earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for one-off items, slipped 1.3% to 4.41 billion euros ($4.76 billion), above an average analyst estimate of 4.15 billion euros posted on the company's website.

"The Pharmaceuticals Division saw gains in growth and profitability, and the Crop Science Division outperformed in a difficult market," Bayer said in a statement.

Shares in the group were up 2.3% shortly after the 0700 GMT open.

CEO Bill Anderson said in March he would suspend for up to three years any preparations to break apart the German maker of pharmaceuticals, crop protection products and consumer health remedies.

His focus is instead on changing Bayer's management structure as well as on cutting debt and dealing with U.S. lawsuits.

Anderson, who became CEO in June 2023, has had a tumultuous start with a continued wave of litigation about an alleged cancer-causing effect of weedkiller glyphosate and a major setback in drug development late last year.

Last month, he clearly won a confidence vote at his first annual general meeting at the helm of the embattled healthcare and agriculture group, defying a challenge from one German fund managing house.

The company said on Tuesday that based on end-of-March exchange rates, EBITDA before special items would likely come in between 10.2 billion and 10.8 billion euros in 2024, compared with a previous target range of between 10.4 billion and 11 billion euros.

That would be down from 11.7 billion in 2023.

Under Anderson's push to speed up business decisions and slash excess bureaucracy, Bayer cut the equivalent of 1,500 full-time jobs during the first quarter.

The company, which had close to 100,000 staff at the end of 2023, has not published any job reduction targets, saying only cutbacks would be significant.

"The most important measure of our impact will be much greater than a job number or a cost savings target. It will be in our ability to innovate, grow our businesses, and improve life for our customers," the CEO said in the statement.

($1 = 0.9273 euros)

Reporting by Ludwig Burger; Editing by Rachel More, Sherry Jacob-Phillips and Jan Harvey


Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.